1.	Phase I Study of Murine Anti-GD2 Ganglioside Monoclonal Antibody 14G2A in Patients with Metastatic Malignant Melanoma, Small Cell Carcinoma of the Lung, Osteosarcoma, or Neuroblastoma (Summary Last Modified 10/90) Phase: Phase I Type: Treatment Status: Closed Age: physiologic 70 or less Sponsor: Protocol IDs: MDA-DM-88141, NCI-B88-0015, B88-0015
2.	Phase Ia/Ib Study of Murine Monoclonal Anti-GD2 Antibody 14G2a in Patients with Metastatic Melanoma and Small Cell Carcinoma of the Lung (Summary Last Modified 05/91) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Protocol IDs: UAC-164, NCI-B88-0014, B88-0014
3.	Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14G2A plus IL-2, with or without GM-CSF, in Children with Refractory Neuroblastoma or Melanoma (Summary Last Modified 02/94) Phase: Phase I Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: CCG-0901
4.	Phase I Study of MOAB 14.G2A plus IL-2 in Patients with Refractory Melanoma (Summary Last Modified 12/93) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Protocol IDs: WCCC-CO-9292, NCI-B91-0011, B91-0011